Background
==========

Liposarcoma (LS), a rare disease derived from adipocyte progenitor, is the second most common soft tissue sarcoma (STS) affecting adulthood, accounting for approximately 20% of new diagnoses. Extremities (24%) and retroperitoneum (45%) are two predilection sites for LS.[@b1-cmar-10-4727]

With surgical resection maintaining the cornerstone of curative treatment, the 5-year disease-free survival (DFS) and 5-year overall survival (OS) of retroperitoneal liposarcoma (RPLS) were 41%--50% and 54%--70%, respectively.[@b2-cmar-10-4727],[@b3-cmar-10-4727] A number of existing literatures reported the prognostic factors of RPLS.[@b3-cmar-10-4727]--[@b5-cmar-10-4727] However, the inaccuracy and inadequacy of those established parameters for predicting prognosis including multifocality, tumor integrity, histological subtype, margin status, and the Union for International Cancer Control (UICC) TNM stage have gradually been demonstrated in clinical practice. Therefore, a more reliable and more convenient predictor for RPLS patients after radical resection is in urgent need.

Recent studies proved the important role of inflammatory response in tumorigenesis and tumor progression.[@b6-cmar-10-4727]--[@b8-cmar-10-4727] Besides, an increasing number of researches revealed that systemic inflammatory markers such as neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), platelet/monocyte ratio (PMR), and albumin/globulin ratio (AGR) could be utilized to evaluate the prognosis of various malignancies, including colorectal cancer, adrenocortical carcinoma, pancreatic cancer, ovarian cancer, and STS.[@b9-cmar-10-4727]--[@b19-cmar-10-4727] However, there was no literature focusing on the correlation between inflammatory markers and the prognosis of RPLS. As a result, we conducted this study to explore the prognostic value of NLR, PLR, LMR, PMR, and AGR in RPLS patients after radical resection.

Patients and methods
====================

Patient selection
-----------------

This study was approved by the ethics committee of Fudan University Shanghai Cancer Center, and written informed consent was obtained from all patients. The criteria for inclusion were as follows: 1) 18 years of age or older; 2) histologically confirmed diagnosis of LS by two experienced pathologists; 3) radically resected (R0/R1 resection) localized disease (without distant metastasis) at the time of surgery; 4) no metabolic, infectious, chronic inflammatory, or autoimmune diseases; 5) no treatment of antibiotics, steroid, chemotherapy, or radiotherapy before surgery; and 6) laboratory tests of peripheral blood sample before surgery.[@b19-cmar-10-4727] Ultimately, 100 patients with RPLS who underwent radical resection between September 2004 and October 2017 at Fudan University Shanghai Cancer Center were included in this study.

The comprehensive information of age, gender, tumor size, admission status, and treatment records were obtained from medical history. Histological subtype was categorized into well-differentiated LS (WDLS), dedifferentiated LS (DDLS), myxoid LS (MLS), round cell LS (RLS), and pleomorphic LS (PLS) on the basis of the Evans classification.[@b20-cmar-10-4727] WDLS and MLS are low-grade tumors, which featured a low frequency of metastasis, whereas DDLS, RLS, and PLS are high-grade tumors with more aggressive biological behavior leading to worse prognosis.[@b21-cmar-10-4727],[@b22-cmar-10-4727] Multifocal disease was defined as having more than one distinct tumor nodules. Tumor integrity was classified into fragmentary group (piecemeal resection or tumor rupture during resection) and intact group on the basis of operative report and/or pathology report. The results of laboratory tests including pretreatment hematologic cell counts and albumin and globulin level were obtained from medical records.

The NLR was derived by dividing the neutrophil count by the lymphocyte count; the PLR was derived by dividing the platelet count by the lymphocyte count; the LMR was derived by dividing the lymphocyte count by the monocyte count; the PMR was derived by dividing the platelet count by the monocyte count; and the AGR was obtained by dividing the albumin level by the globulin level.

Follow-up data
--------------

After radical resection, all patients were arranged for surveillance imaging such as ultrasound, computed tomography, or magnetic resonance every 3--4 months for the first year, then every 6 months for the next 2 years, and then yearly.

OS was counted as the interval from the date of surgery to the date of death (event) related to the disease (or complications). DFS was calculated from the date of surgery to the date of disease relapse (local recurrence or distant metastases) or death without evidence of disease relapse. For patients alive and without records of disease relapse, follow-up was censored at the time of last follow-up. Follow-up data were collected by phone call and/or outpatient records. All 100 patients were continuously followed up to March 2018, the time of final follow-up, or the date of death.

Statistical analysis
--------------------

SPSS 21.0 (IBM Corporation, Armonk, NY, USA) was applied for statistical analysis. Differences between groups were compared by the chi-squared test. Receiver operating characteristic (ROC) analyses were conducted with OS as endpoint. The optimal cutoff values of LMR, NLR, PMR, PLR, and AGR were determined at the point of the maximal Youden's index.[@b18-cmar-10-4727],[@b23-cmar-10-4727] The median OS and DFS were calculated using the Kaplan--Meier method. Curves of DFS and OS were also obtained by the Kaplan--Meier method. Log-rank test was applied to compare the survival between groups. Cox proportional hazards regression modeling was used to perform univariate and multivariate analyses. The factors that identified statistical significance in the univariate analysis were then put into multivariate analysis. All tests were two sided with a significance level set at *P*\<0.05.

Results
=======

Patient characteristics and optimal cutoff values
-------------------------------------------------

The clinicopathological characteristics of the 100 RPLS patients were listed at length in [Table 1](#t1-cmar-10-4727){ref-type="table"}. There were 48 males and 52 females. The median age was 50 years (range, 27--78 years). Fifty-eight patients presented with primary tumor, while 42 with recurrent disease. The median tumor size was 18 cm (range, 2--50 cm), \<20 cm in 56 patients and ≥20 cm in 44 patients. Eighty-eight patients underwent surgery with intact tumor, while 12 received piecemeal resection. Concomitant organ resection was performed on 52 patients. Twenty-five patients presented with multifocal disease. In case of histological subtypes, 39 patients were of WDLS, 51 DDLS, 3 MLS, 2 RLS, and 5 PLS. As a result, there were 42 patients with low-grade tumors, while 58 with high-grade tumors. Of 100 patients, 10 patients received adjuvant chemotherapy, seven gained adjuvant radiotherapy, and five obtained both therapies. The average cell count (×10^9^/L) of neutrophil, lymphocyte, platelet, and monocyte was 3.93±1.56, 1.58±0.48, 245.50±91.47, and 0.48±0.16, respectively. The average level (g/L) of albumin and globulin were 41.28±5.32 and 29.66±5.43, respectively.

According to the ROC analysis ([Figure 1](#f1-cmar-10-4727){ref-type="fig"}), the area under the curve (AUC) for NLR, PLR, LMR, PMR, and AGR were 0.548 (95% CI, 0.434--0.658, *P*=0.4615), 0.537 (95% CI, 0.423--0.648, *P*=0.5772), 0.651 (95% CI, 0.538--0.753, *P*=0.0164), 0.647 (95% CI, 0.533--0.749, *P*=0.0189), and 0.686 (95% CI, 0.574--0.784, *P*=0.0020), respectively. The maximal Youden's index for NLR, PLR, LMR, PMR, and AGR were 0.132, 0.140, 0.329, 0.299, and 0.377, respectively. The optimal cutoff value for NLR, PLR, LMR, PMR, and AGR were 2.74, 212, 3, 610, and 1.55, respectively. Details of ROC analysis were summarized in [Table 2](#t2-cmar-10-4727){ref-type="table"}.

Data analysis
-------------

At the end of the study follow-up, 67 patients remained alive, and 66 patients suffered disease recurrence. The 5-year DFS and 5-year OS rates were 20.6% and 64.7%, respectively. The median follow-up duration, median DFS, and median OS were 53, 27, and 86 months, respectively.

In univariate analysis, shorter OS was significantly associated with fragmentary resection (median OS, 33 vs 115 months, *P*=0.004), multifocality (median OS, 48 vs 97 months, *P*=0.001), high-grade tumor (median OS, 58 vs 158 months, *P*\<0.001), low LMR (median OS, 48 vs 86 months, *P*\<0.001), low PMR (median OS, 72 vs 158 months, *P*=0.030; [Figure 2A](#f2-cmar-10-4727){ref-type="fig"}), and low AGR (median OS, 66 vs 81 months, *P*=0.026). Shorter DFS was significantly associated with recurrent disease (median DFS, 21 vs 30 months, *P*=0.031), fragmentary resection (median DFS, 11 vs 28 months, *P*=0.011), multifocality (median DFS, 12 vs 31 months, *P*\<0.001), high-grade tumor (median DFS, 21 vs 46 months, *P*\<0.001), high PLR (median DFS, 20 vs 30 months, *P*=0.050), and low LMR (median DFS, 13 vs 31 months, *P*\<0.001; [Figure 2B](#f2-cmar-10-4727){ref-type="fig"}). Details of univariate analysis were presented in [Table 3](#t3-cmar-10-4727){ref-type="table"}.

In multivariate analysis, fragmentary resection (OS: HR, 4.602, 95% CI, 1.851--11.438, *P*=0.001; DFS: HR, 2.697, 95% CI, 1.350--5.385, *P*=0.005), multifocality (OS: HR, 4.265, 95% CI, 1.836--9.906, *P*=0.001; DFS: HR, 3.415, 95% CI, 1.737--6.716, *P*\<0.001), high-grade tumor (OS: HR, 6.515, 95% CI, 1.773--23.946, *P*=0.005; DFS: HR, 1.915, 95% CI, 1.059--3.463, *P*=0.031), and low LMR (OS: HR, 3.897, 95% CI, 1.681--9.033, *P*=0.002; DFS: HR, 2.854, 95% CI, 1.392--5.851, *P*=0.004) remained statistically significant for both OS and DFS. Details of multivariate analysis were listed in [Table 4](#t4-cmar-10-4727){ref-type="table"}.

Discussion
==========

Increasing evidences revealed the correlation between inflammatory biomarkers and the prognosis of diversified malignancies, including STS.[@b9-cmar-10-4727]--[@b19-cmar-10-4727] However, almost all of the existing literatures about STS were histology non-specific, which mingled various histologic subtypes of STS.[@b9-cmar-10-4727],[@b14-cmar-10-4727]--[@b17-cmar-10-4727] As known earlier, STS represented a complex group of neoplasms of mesenchymal origin, and the prognosis might vary markedly based on different histologic subtypes and different tumor locations. Therefore, we argued that it would be more helpful in clinical practice if we could conduct histology- and location-specific researches.

This is the first study, to the best of our knowledge, that focuses specifically on the prognostic values of the inflammatory biomarkers in radically resected RPLS patients. In addition, our findings prove preoperative LMR to be an independent prognostic factor of both OS and DFS for radically resected RPLS patients.

In this study, we retrospectively assessed the prognostic values of NLR, PLR, LMR, PMR, and AGR by using the clinicopathologic data of 100 patients. NLR was the most common reported inflammatory index for STS.[@b9-cmar-10-4727],[@b15-cmar-10-4727],[@b16-cmar-10-4727] However, we did not observe any significant effect of NLR on patients' outcome in this cohort. There was also a study showing that low PLR was associated with poor survival among STS patients, an effect that was not observed in this study.[@b17-cmar-10-4727] The absence of prognostic value of NLR and PLR in this cohort might be explained by the following two reasons. First, perhaps NLR and PLR possessed no prognostic value for RPLS indeed. As previous researches contained various histologic subtypes of STS, the correlations between RPLS and NLR/PLR were probably obscured by the large number of the entire samples.[@b9-cmar-10-4727],[@b15-cmar-10-4727]--[@b17-cmar-10-4727] Second, our samples might be not large enough to discover their prognostic values. In case of PMR, there was no report showing the prognostic significance of PMR in patients with malignancy. In this study, low PMR was adversely associated with OS (*P*=0.030) in univariate analysis. However, it lost the significance in multivariate analysis (*P*=0.711). In the previous report that comprised 5,336 patients from our institution, low AGR was proven to be an independent predicator for colorectal cancer patients after curative resection.[@b19-cmar-10-4727] In this study, low AGR group showed worse OS in univariate analysis (*P*=0.026), but it was not statistically significant in multivariate analysis (*P*=0.677). In terms of LMR, pretreatment LMR was reported to be independently associated with patients' outcomes among various malignancies, including colorectal cancer, malignant pleural mesothelioma, hepatocellular carcinoma, gastric cancers, and STS.[@b14-cmar-10-4727],[@b19-cmar-10-4727],[@b24-cmar-10-4727]--[@b26-cmar-10-4727] Szkandera et al[@b14-cmar-10-4727] reported that LMR\<2.85 was associated with worse prognosis in STS patients. In this research, low LMR was proven to be an independent adverse prognostic factor for both OS (*P*=0.002) and DFS (*P*=0.004). Probably owing to the better specificity of samples of this study, the optimal cutoff value of LMR was slightly higher in this study than that in the study by Szkandera et al[@b14-cmar-10-4727] (3 vs 2.85).

Despite we discovered the prognostic significance of low LMR in radically resected RPLS patients, the biological mechanism behind this phenomenon remained unknown. Nevertheless, we could find some clues through previous experimental studies.

Generally, solid tumors are infiltrated with leukocytes, and the interactions between tumor cells and white blood cells have substantial effects on tumor progression.[@b14-cmar-10-4727] As known earlier, lymphocytes represent the host antitumor immunity, playing a pivotal role in cytotoxic cell death and the inhibition of tumor cell proliferation and migration.[@b8-cmar-10-4727],[@b27-cmar-10-4727],[@b28-cmar-10-4727] Lymphocytopenia has been observed in various malignancies, which was assumed to be responsible for the insufficient immunologic response to the tumor, consequently leading to tumor growth, invasion, and metastases.[@b29-cmar-10-4727],[@b30-cmar-10-4727] Furthermore, peripheral monocytes have been reported to be connected with the formation and the presence of tumor-associated macrophages (TAMs).[@b31-cmar-10-4727] TAMs are capable of releasing soluble factors that stimulate neo-angiogenesis, cell proliferation, and migration of tumor.[@b8-cmar-10-4727],[@b32-cmar-10-4727] Elevated TAMs, which may be reflected by elevated circulating monocytes, have been revealed to be correlated with poor prognosis.[@b32-cmar-10-4727],[@b33-cmar-10-4727] As mentioned above, decreased lymphocytes count and increased monocytes count reflect deficient antitumor immunity and elevated malignant potentiality, respectively. As a result, we can make sense of the correlation between low LMR and poor prognosis in RPLS patients.

In case of the biology of RPLS concerning inflammation and immune system, there were few literatures mentioning this at present.[@b34-cmar-10-4727]--[@b36-cmar-10-4727] Tseng et al[@b34-cmar-10-4727] observed tertiary lymphoid structures (TLSs) formed by tumor-infiltrating lymphocytes (TILs) in fresh surgical specimens of eight RP WDLS and RP DDLS patients. However, TLSs were associated with worse clinical outcome according to the statistical analysis. On the contrary, TLSs were reported to be associated with favorable patients' outcomes in non-small cell lung cancer and colorectal cancer.[@b35-cmar-10-4727],[@b36-cmar-10-4727] Thus, further studies with large number and more histologic subtypes of cases are needed to clarify the correlation between TILs and the biology of RPLS.

This study demonstrates the significant role of pretreatment LMR in RPLS patients after radical resection. As the immunotherapy advances at a miraculous pace, new drugs that target lymphocytes and monocytes may improve the outcomes of RPLS patients with high pretreatment LMR.

The principal advantages of this study are the specificity of the research sample and the relatively long follow-up period. The main limitation is the small sample size. Further studies with large numbers of patients are required in the future.

Conclusion
==========

This study focuses on the correlation between inflammatory biomarkers and the prognosis in radically resected RPLS for the first time. Low LMR is demonstrated to be an independent predicator for both DFS and OS. We hope our research may facilitate further studies and clinical practice.
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###### 

Patients' characteristics

  Variable           Total (N=100)   LMR≤3 (n=24)   LMR\>3 (n=76)   *P*-value
  ------------------ --------------- -------------- --------------- -----------
  Gender                                                            
   Male              48              13             35              0.488
   Female            52              11             41              
  Age (years)                                                       
   ≥50               53              12             41              0.736
   \<50              47              12             35              
  Presentation                                                      
   Recurrent         42              9              33              0.608
   Primary           58              15             43              
  Tumor size (cm)                                                   
   ≥20               44              11             33              0.836
   \<20              56              13             43              
  Tumor integrity                                                   
   Fragmentary       12              4              8               0.420
   Intact            88              20             60              
  Organ resection                                                   
   Yes               52              15             37              0.238
   No                48              9              39              
  Multifocality                                                     
   Yes               25              5              20              0.589
   No                75              19             56              
  Tumor grade                                                       
   High grade        58              20             38              
   Low grade         42              4              38              0.004
  Adjuvant therapy                                                  
   Yes               22              6              16              0.684
   No                78              18             60              
  NLR                                                               
   \>2.74            32              19             13              \<0.001
   ≤2.74             68              5              63              
  PLR                                                               
   \>212             21              17             4               \<0.001
   ≤212              79              7              72              
  PMR                                                               
   ≤610              54              7              47              0.058
   \>610             46              17             29              
  AGR                                                               
   ≤1.55             62              21             41              0.003
   \>1.55            38              3              35              

**Abbreviations:** AGR, albumin/globulin ratio; LMR, lymphocyte/monocyte ratio; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; PMR, platelet/monocyte ratio.

###### 

Results of ROC curve analyses

  Variable   AUC     95% CI         *P*-value   Maximal Youden's index   Optimal cutoff
  ---------- ------- -------------- ----------- ------------------------ ----------------
  NLR        0.548   0.434--0.658   0.4615      0.132                    2.74
  PLR        0.537   0.423--0.648   0.5772      0.140                    212
  LMR        0.651   0.538--0.753   0.0164      0.329                    3
  PMR        0.647   0.533--0.749   0.0189      0.299                    610
  AGR        0.686   0.574--0.784   0.0020      0.377                    1.55

**Abbreviations:** AGR, albumin/globulin ratio; AUC, area under the curve; LMR, lymphocyte/monocyte ratio; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; PMR, platelet/monocyte ratio; ROC, receiver operating characteristic.

###### 

Details of univariate analyses

  Variable           DFS               OS                                                                      
  ------------------ ----------------- ------------------- --------- ------------------- --------------------- ---------
  Gender                                                                                                       
   Male              28 (21.9--34.1)   0.88 (0.54--1.43)   0.592     72 (51.1--92.9)     1.29 (0.65--2.56)     0.473
   Female            23 (14.4--31.6)                                 115 (55.8--174.2)                         
  Age (years)                                                                                                  
   ≥50               28 (22.3--33.7)   0.87 (0.54--1.42)   0.570     86 (54.7--117.3)    1.13 (0.57--2.25)     0.730
   \<50              22 (19.6--24.4)                                 81 (35.2--126.8)                          
  Presentation                                                                                                 
   Recurrent         21 (15.1--26.9)   1.68 (1.03--2.74)   0.031     97 (49.5--144.5)    1.09 (0.55--2.17)     0.804
   Primary           30 (25.2--34.8)                                 81 (59.6--102.4)                          
  Tumor size (cm)                                                                                              
   ≥20               31 (24.7--37.3)   0.86 (0.53--1.40)   0.536     81 (55.3--106.7)    1.10 (0.55--2.18)     0.795
   \<20              24 (16.9--31.1)                                 97 (53.1--140.9)                          
  Tumor integrity                                                                                              
   Fragmentary       11 (5.9--16.1)    2.26 (1.17--4.35)   0.011     33 (27.4--38.6)     3.03 (1.38--6.64)     0.004
   Intact            28 (23.2--32.8)                                 115 (59.1--170.9)                         
  Organ resection                                                                                              
   No                24 (14.4--33.6)   1.14 (0.69--1.85)   0.612     81 (52.2--109.8)    0.87 (0.44--1.73)     0.689
   Yes               31 (18.5--43.5)                                 86 (50.7--121.3)                          
  Multifocality                                                                                                
   Yes               12 (9.3--14.7)    2.91 (1.66--5.09)   \<0.001   48 (35.2--60.8)     3.11 (1.55--6.24)     0.001
   No                31 (26.1--35.9)                                 97 (74.6--119.4)                          
  Tumor grade                                                                                                  
   High grade        21 (15.2--26.8)   2.67 (1.55--4.63)   \<0.001   58 (40.1--75.9)     10.30 (3.13--33.88)   \<0.001
   Low grade         46 (18.8--73.2)                                 158                                       
  Adjuvant therapy                                                                                             
   Yes               21 (16.7--25.3)   1.60 (0.92--2.78)   0.072     66 (48.3--83.7)     1.82 (0.86--3.82)     0.111
   No                28 (21.1--34.9)                                 97 (59.3--134.7)                          
  NLR                                                                                                          
   \>2.74            22 (18.1--25.9)   1.44 (0.85--2.42)   0.166     72 (55.6--88.4)     1.67 (0.82--3.38)     0.151
   ≤2.74             30 (24.4--35.6)                                 97 (61.8--132.2)                          
  PLR                                                                                                          
   \>212             20 (3.6--36.4)    1.78 (0.98--3.24)   0.050     48 (20.7--75.3)     1.96 (0.89--4.29)     0.088
   ≤212              30 (24.5--35.5)                                 81 (65.3--96.7)                           
  LMR                                                                                                          
   ≤3                13 (2.7--23.3)    2.66 (1.55--4.58)   \<0.001   48 (17.0--79.0)     3.44 (1.70--6.94)     \<0.001
   \>3               31 (24.4--37.6)                                 86 (67.9--104.1)                          
  PMR                                                                                                          
   ≤610              24 (18.6--29.4)   1.48 (0.89--2.44)   0.122     72 (51.7--92.3)     2.37 (1.06--5.28)     0.030
   \>610             31 (10.9--51.1)                                 158                                       
  AGR                                                                                                          
   ≤1.55             26 (17.6--34.4)   1.26 (0.76--2.08)   0.368     66 (50.7--81.3)     2.52 (1.09--5.85)     0.026
   \>1.55            27 (15.9--38.1)                                 81 (48.7--113.3)                          

**Abbreviations:** AGR, albumin/globulin ratio; DFS, disease-free survival; LMR, lymphocyte/monocyte ratio; NLR, neutrophil/lymphocyte ratio; OS, overall survival; PLR, platelet/lymphocyte ratio; PMR, platelet/monocyte ratio; ROC, receiver operating characteristic.

###### 

Details of multivariate analyses

  Variable                                 DFS                    OS                                
  ---------------------------------------- ---------------------- --------- ----------------------- -------
  Presentation (primary vs recurrent)      1.142 (0.651--2.003)   0.643                             
  Tumor integrity (intact vs fragmented)   2.697 (1.350--5.385)   0.005     4.602 (1.851--11.438)   0.001
  Multifocality (no vs yes)                3.415 (1.737--6.716)   \<0.001   4.265 (1.836--9.906)    0.001
  Tumor grade (low vs high)                1.915 (1.059--3.463)   0.031     6.515 (1.773--23.946)   0.005
  PLR (\>212 vs ≤212)                      1.191 (0.545--2.601)   0.31                              
  LMR (\>3 vs ≤3)                          2.854 (1.392--5.851)   0.004     3.897 (1.681--9.033)    0.002
  PMR (\>610 vs ≤610)                                                       1.230 (0.519--2.913)    0.639
  AGR (≤1.55 vs \>1.55)                                                     1.280 (0.458--3.579)    0.638

**Abbreviations:** AGR, albumin/globulin ratio; DFS, disease-free survival; LMR, lymphocyte/monocyte ratio; OS, overall survival; PLR, platelet/lymphocyte ratio; PMR, platelet/monocyte ratio.
